Clinical Trial

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2020-04-07; most recent amendment 2026-02-09.
Status change: Recruiting → Active, Not Recruiting 2026-01-26
Status change: Not Yet Recruiting → Recruiting 2020-10-01
Trial Details
NCT Number NCT04340141
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Enrollment 358 participants
Start Date 2020-10-13
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-10